Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722137 | 0.86 | MEN1 (0.46) | NPSR1HPGDHRH3RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL8132994 | 0.84 | MEN1 (0.46) | NPSR1HPGDHRH3ACHEMEN1 | |
| SCHEMBL1949284 | 0.83 | ALDH1A1 (0.44) | NPSR1HPGDHRH3RAB9ANPC1 | |
| SCHEMBL3170264 | 0.79 | KMT2A (0.46) | HPGDHRH3BCHEACHERAB9A | |
| SCHEMBL10123175 | 0.75 | KMT2A (0.41) | HRH3BCHEACHERAB9ANPC1 | |
| SCHEMBL6800384 | 0.74 | GBA1 (0.46) | NPSR1BCHEACHERAB9ANPC1 | |
| SCHEMBL1039304 | 0.72 | MEN1 (0.44) | BCHERAB9ANPC1MEN1KMT2A | |
| SCHEMBL6096807 | 0.71 | HTR1A (0.51) | HRH3BCHEACHE | |
| SCHEMBL3485508 | 0.71 | HPGD (0.51) | NPSR1HPGDACHERAB9ANPC1 | |
| SCHEMBL7171113 | 0.71 | KMT2A (0.40) | NPSR1BCHEACHERAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136801-A1 | Novel Compounds | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136801-A1 | Novel Compounds | C1R, RB1, CNKSR1 | NPSR1 201/4885HPGD 4048/4885HRH3 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.